Back to Authors

Salati, Massimiliano

Mayo Clinic

University of Modena and Reggio Emilia

Citations 2

The NAMPT Inhibitor FK866 in Combination with Cisplatin Reduces Cholangiocarcinoma Cells Growth
Pant, Kishor , Richard, Seth , Peixoto, Estanislao , Yin, Jun , Seelig, Davis , Carotenuto, Pietro , Salati, Massimiliano, Franco, Brunella , Roberts, Lewis R. , Gradilone, Sergio A. , Roberts, Lewis R , Gradilone, Sergio A , Salati, Massimiliano

Cells | March 1, 2023 | Volume: 12 | Issue: 5 | Pages: 775

10.3390/cells12050775 Get It

It is well established that Cholangiocarcioma (CCA) drug resistance plays a crucial role in the spread and survival of cancer cells. The major enzyme in the nicotinamide-adenine dinucleotide (NAD+)-mediated pathways, nicotinamide phosphoribosyltransferase (NAMPT), is essential for cancer cell survival and metastasis. Previous research has shown that the targeted NAMPT inhibitor FK866 reduces cancer cell viability and triggers cancer cell death; however, whether FK866 affects CCA cell survival has not been addressed before. We show herein that NAMPT is expressed in CCA cells, and FK866 suppresses the capacity of CCA cells to grow in a dose-dependent manner. Furthermore, by preventing NAMPT activity, FK866 significantly reduced the amount of NAD+ and adenosine 5′-triphosphate (ATP) in HuCCT1, KMCH, and EGI cells. The present study’s findings further show that FK866 causes changes in mitochondrial metabolism in CCA cells. Additionally, FK866 enhances the anticancer effects of cisplatin in vitro. Taken together, the results of the current study suggest that the NAMPT/NAD+ pathway may be a possible therapeutic target for CCA, and FK866 may be a useful medication targeting CCA in combination with cisplatin.
Histone Deacetylase Sirtuin 1 Promotes Loss of Primary Cilia in Cholangiocarcinoma
Pant, Kishor , Peixoto, Estanislao , Richard, Seth , Biswas, Aalekhya , O’Sullivan, M. Gerard , Giama, Nasra H., Ha, Yeonjung , Yin, Jun , Carotenuto, Pietro , Salati, Massimiliano, Ren, Yanan , Yang, Rendong , Roberts, Lewis R. , Gradilone, Sergio A. , O’Sullivan, M. Gerard , Giama, Nasra, Gradilone, Sergio A , Roberts, Lewis R , O'Sullivan, M Gerard , Salati, Massimiliano , Franco, Brunella

Hepatology | July 29, 2021 | Volume: 74 | Issue: 6 | Pages: 3235-3248

10.1002/hep.32080 Get It

Background and Aims Sirtuin 1 (SIRT1) is a complex NAD+‐dependent protein deacetylase known to act as a tumor promoter or suppressor in different cancers. Here, we describe a mechanism of SIRT1‐induced destabilization of primary cilia in cholangiocarcinoma (CCA). Approach and Results A significant overexpression of SIRT1 was detected in human CCA specimens and CCA cells including HuCCT1, KMCH, and WITT1 as compared with normal cholangiocytes (H69 and NHC). Small interfering RNA (siRNA)‐mediated knockdown of SIRT1 in HuCCT1 cells induced cilia formation, whereas overexpression of SIRT1 in normal cholangiocytes suppressed ciliary expression. Activity of SIRT1 was regulated by presence of NAD+ in CCA cells. Inhibition of NAD ‐producing enzyme nicotinamide phosphoribosyl transferase increased ciliary length and frequency in CCA cells and in SIRT1‐overexpressed H69 cells. Furthermore, we also noted that SIRT1 induces the proteasomal mediated degradation of ciliary proteins, including α‐tubulin, ARL13B, and KIF3A. Moreover, overexpression of SIRT1 in H69 and NHC cells significantly induced cell proliferation and, conversely, SIRT1 inhibition in HuCCT1 and KMCH cells using siRNA or sirtinol reduced cell proliferation. In an orthotopic transplantation rat CCA model, the SIRT1 inhibitor sirtinol reduced tumor size and tumorigenic proteins (glioma‐associated oncogene 1, phosphorylated extracellular signal‐regulated kinase, and IL‐6) expression. Conclusions In conclusion, these results reveal the tumorigenic role of SIRT1 through modulation of primary cilia formation and provide the rationale for developing therapeutic approaches for CCA using SIRT1 as a target.